Table 1 Frequencies of known mutations conferring resistance to first-line drugs among all isolates, phenotypically resistant isolates, and susceptible isolates in the Hanoi sample set (Nā€‰=ā€‰332).

From: Whole genome sequencing, analyses of drug resistance-conferring mutations, and correlation with transmission of Mycobacterium tuberculosis carrying katG-S315T in Hanoi, Vietnam

Drug resistance-conferring mutations

Study population

n (%)

Phenotypically resistant isolates

n (%)

Phenotypically susceptible isolates

n (%)

Isoniazid

Nā€‰=ā€‰332

Nā€‰=ā€‰88

Nā€‰=ā€‰244

(āˆ’)

233 (70.2)

8 (9.1)

225 (92.2)

katG (S315T)

87 (26.2)

75 (85.3)

12 (4.9)

Rv1482c-fabG1 (C-15T)

7 (2.1)

3 (3.4)

4 (1.6)

Rv1482c-fabG1 (C-15T), inhA (S94A)

1 (0.3)

1 (1.1)

0 (0.0)

Rv1482c-fabG1 (C-15T), katG (S315N)

1 (0.3)

1 (1.1)

0 (0.0)

katG (G234R)

1 (0.3)

0 (0.0)

1 (0.4)

katG (S315G)

1 (0.3)

0 (0.0)

1 (0.4)

katG (W191R)

1 (0.3)

0 (0.0)

1 (0.4)

Streptomycin

Nā€‰=ā€‰332

Nā€‰=ā€‰86

Nā€‰=ā€‰246

(āˆ’)

259 (78.0)

23 (26.6)

236 (96.0)

rpsL (K43R)

44 (13.3)

42 (48.8)

2 (0.8)

rrs (A514C)

14 (4.2)

11 (12.8)

3 (1.2)

rpsL (K88R)

6 (1.8)

6 (7.0)

0 (0.0)

gid (L16R), rrs (A514C)

1 (0.3)

1 (1.2)

0 (0.0)

rpsL (K43R), rrs (A1401G)

1 (0.3)

1 (1.2)

0 (0.0)

rrs (A907T)

1 (0.3)

1 (1.2)

0 (0.0)

rrs (C517T)

2 (0.6)

1 (1.2)

1 (0.4)

rrs (T1239C)

1 (0.3)

0 (0.0)

1 (0.4)

rpsL (K88T)

1 (0.3)

0 (0.0)

1 (0.4)

gid (L16R)

2 (0.6)

0 (0.0)

2 (0.8)

Rifampicin

Nā€‰=ā€‰332

Nā€‰=ā€‰13

Nā€‰=ā€‰319

(āˆ’)

310 (93.4)

1 (7.7)

309 (96.9)

rpoB (S450L)

9 (2.7)

4 (30.8)

5 (1.6)

rpoB (H445D)

4 (1.2)

4 (30.8)

0 (0.0)

rpoB (H445L)

2 (0.6)

2 (15.4)

0 (0.0)

rpoB (K446Q)

1 (0.3)

1 (7.7)

0 (0.0)

rpoB (Q432K)

1 (0.3)

1 (7.7)

0 (0.0)

rpoB (L452P)

1 (0.3)

0 (0.0)

1 (0.3)

rposB (S450L), rpoB (E761D)

1 (0.3)

0 (0.0)

1 (0.3)

rpoB (L430P)

3 (0.9)

0 (0.0)

3 (0.9)

Ethambutol

Nā€‰=ā€‰332

Nā€‰=ā€‰5

Nā€‰=ā€‰327

(āˆ’)

303 (91.3)

0 (0.0)

303 (92.7)

embB (M306V)

6 (1.8)

3 (60.0)

3 (0.9)

embB (L370R)

13 (3.9)

1 (20.0)

12 (3.7)

embC-embA (C-12T)

1 (0.3)

1 (20.0)

0 (0.0)

embB (D354A)

1 (0.3)

0 (0.0)

1 (0.3)

embB (G406A)

2 (0.6)

0 (0.0)

2 (0.6)

embB (G406D)

1 (0.3)

0 (0.0)

1 (0.3)

embB (M306I)

4 (1.2)

0 (0.0)

4 (1.2)

embB (Q497R)

1 (0.3)

0 (0.0)

1 (0.3)

Pyrazinamide

Nā€‰=ā€‰332

Nā€‰=ā€‰9

Nā€‰=ā€‰323

(āˆ’)

319 (96.1)

4 (44.4)

315 (97.5)

pncA (Q141P)

3 (0.9)

2 (22.2)

1 (0.3)

pncA (L159R)

1 (0.3)

1 (11.1)

0 (0.0)

pncA (S59P)

1 (0.3)

1 (11.1)

0 (0.0)

pncA-Rv2044c (T-11C)

3 (0.9)

1 (11.1)

2 (0.6)

pncA (A46V)

1 (0.3)

0 (0.0)

1 (0.3)

pncA (I31S)

1 (0.3)

0 (0.0)

1 (0.3)

pncA (Q10P)

1 (0.3)

0 (0.0)

1 (0.3)

pncA (Q10R)

1 (0.3)

0 (0.0)

1 (0.3)

pncA (S104R)

1 (0.3)

0 (0.0)

1 (0.3)

Back to article page